CONTACT US
Home > Inhibitors/Agonists> > PF-05231023
1037589-69-7-PF-05231023 PF-05231023

PF-05231023

For research use only. Not for therapeutic Use.

  • CAT Number: I008677
  • CAS Number: 1037589-69-7
  • Molecular Formula: C26H32N4O8
  • Molecular Weight: 528.562
  • Purity: ≥95%
Inquiry Now
Related Small Molecules: Latrepirdine     Praeruptorin A     LCL161    

PF-05231023 (Cat.No:I008677) is a Long-Acting FGF21 mimetic. PF-05231023 Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects.


Catalog Number I008677
CAS Number 1037589-69-7
Synonyms

PF-05231023; PF05231023; PF05231023; PF-5231023; PF5231023; PF5231023.;2,5-Dihydro-2,5-dioxo-N-[2-[2-[3-oxo-3-[[4-[3-oxo-3-(2-oxo-1-azetidinyl)propyl]phenyl]amino]propoxy]ethoxy]ethyl]-1H-pyrrole-1-propanamide

Molecular Formula C26H32N4O8
Purity ≥95%
Target PROTAC Linkers
Solubility Soluble in DMSO
Storage 0 - 4 °C for short term, or -20 °C for long term
InChI InChI=1S/C26H32N4O8/c31-21(9-13-29-24(34)7-8-25(29)35)27-12-16-38-18-17-37-15-11-22(32)28-20-4-1-19(2-5-20)3-6-23(33)30-14-10-26(30)36/h1-2,4-5,7-8H,3,6,9-18H2,(H,27,31)(H,28,32)
InChIKey BJDLYWUPKGDHCF-UHFFFAOYSA-N
SMILES O=C(NCCOCCOCCC(NC1=CC=C(CCC(N2C(CC2)=O)=O)C=C1)=O)CCN3C(C=CC3=O)=O
Reference

<br />
1:PF-05231023, a long-acting FGF21 analogue, decreases body weight by reduction of food intake in non-human primates. Thompson WC, Zhou Y, Talukdar S, Musante CJ.J Pharmacokinet Pharmacodyn. 2016 Aug;43(4):411-25. doi: 10.1007/s10928-016-9481-1. Epub 2016 Jul 12. PMID: 27405817 Free PMC Article<br />
2:A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects. Talukdar S, Zhou Y, Li D, Rossulek M, Dong J, Somayaji V, Weng Y, Clark R, Lanba A, Owen BM, Brenner MB, Trimmer JK, Gropp KE, Chabot JR, Erion DM, Rolph TP, Goodwin B, Calle RA.Cell Metab. 2016 Mar 8;23(3):427-40. doi: 10.1016/j.cmet.2016.02.001. PMID: 26959184 Free Article<br />
3:Pharmacokinetics and pharmacodynamics of PF-05231023, a novel long-acting FGF21 mimetic, in a first-in-human study. Dong JQ, Rossulek M, Somayaji VR, Baltrukonis D, Liang Y, Hudson K, Hernandez-Illas M, Calle RA.Br J Clin Pharmacol. 2015 Nov;80(5):1051-63. doi: 10.1111/bcp.12676. Epub 2015 Jul 29. PMID: 25940675 Free PMC Article<br />
4:Mechanistic investigation of the preclinical pharmacokinetics and interspecies scaling of PF-05231023, a fibroblast growth factor 21-antibody protein conjugate. Giragossian C, Vage C, Li J, Pelletier K, Pich&eacute;-Nicholas N, Rajadhyaksha M, Liras J, Logan A, Calle RA, Weng Y.Drug Metab Dispos. 2015 Jun;43(6):803-11. doi: 10.1124/dmd.114.061713. Epub 2015 Mar 24. PMID: 25805881 Free Article<br />
5:Pharmacokinetics (PK), pharmacodynamics (PD) and integrated PK/PD modeling of a novel long acting FGF21 clinical candidate PF-05231023 in diet-induced obese and leptin-deficient obese mice. Weng Y, Chabot JR, Bernardo B, Yan Q, Zhu Y, Brenner MB, Vage C, Logan A, Calle R, Talukdar S.PLoS One. 2015 Mar 19;10(3):e0119104. doi: 10.1371/journal.pone.0119104. eCollection 2015. PMID: 25790234 Free PMC Article

Request a Quote